Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Savolitinib as a novel treatment regimen for pulmonary sarcomatoid carcinoma with MET exon 14 skipping mutation.

Asian journal of surgery - 1 Jul 2024

Wang Yan, Bu Yijie, Che Guowei

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Acrylamides
Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins c-met

Share to Treatment Outcome

Source

Identifiers

PMID: 38599970
DOI: 10.1016/j.asjsur.2024.03.165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Savolitinib as a novel treatment regimen for pulmonary sarcomatoid carcinoma with MET exon 14 skipping mutation.PMID 38599970Read ↗

Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation.Semantic proximity Read ↗

Savolitinib for non-small cell lung cancer.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations: Essential Considerations for Current Management of Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant diseaseSemantic proximity Read ↗

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.Semantic proximity Read ↗

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.Semantic proximity Read ↗

Savolitinib: A Promising Targeting Agent for CancerSemantic proximity Read ↗

[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.